d1000 Varejo Farma Participações S.A

What it is

Through four retail brands — Drogasmil, Farmalife, Drogarias Tamoio, and Drogaria Rosário — d1000 sells medicines, supplements, and cosmetics from around 300 stores across Rio de Janeiro, Goiás, Mato Grosso, Tocantins, and the Federal District. The holding company was formerly known as Cancun RJ Participações S/A and took its current name in March 2016.

d1000 is the retail arm of the Profarma Group — Profarma being one of Brazil’s largest pharmaceutical distributors, listed separately on B3 under PFRM3. The retail chain and the distributor parent thus share both supply chain and strategic direction.

Who owns it

d1000 operates as a subsidiary of Profarma Distribuidora de Produtos Farmacêuticos S.A. Insiders — effectively Profarma and its controlling shareholders — hold 77.9% of d1000’s shares, while institutional investors account for a further 8.6%, leaving a free float of roughly 13.5% (EODHD; our calculation).

The exact breakdown of Profarma’s own controlling family or group is not disclosed in available public filings reviewed for this profile. d1000’s board is the company’s main decision-making body, tasked with setting general business guidelines and overseeing the executive team.

Who runs it

Marcelo Freitas Cardoso, a business administration graduate of UERJ with 30 years in the pharma industry, has held senior commercial roles at Rhodia Farma, Merck Sharp Dohme, and A Nossa Drogaria. His precise current title at d1000 is not confirmed in available primary sources.

The investor-relations director is Rita Cristiane Ribeiro Carvalho, a finance executive with experience across listed Brazilian companies; she previously served as CFO and IR Director at Valid Soluções S.A. from 2011 to 2021. A further note on her tenure appears under “What to watch” below.

The money, in plain words

Sales have grown at roughly 23–24% a year for two straight years — from BRL 1.75bn (US$340 mn) (~$340m) in FY2023 to BRL 2.67bn (US$518 mn) (~$518m) in FY2025 (our calculation from EODHD). That is impressive top-line momentum for a mid-size retail chain.

The catch is what stays behind. The company keeps less than 1 cent of profit from every real of sales — a net profit margin of 0.85% in FY2025, and 1.20% in FY2024 (our calculation) — which is razor-thin even by the standards of drug retail worldwide.

For every real owners have put in, d1000 earns about 2.6 centavos a year — a return on equity of 2.63% — well below Brazil’s benchmark interest rate and a sign that growth is absorbing capital faster than it is generating returns. At today’s price, investors are paying 14.5 times annual earnings (a price-to-earnings ratio of 14.5×), which is a modest valuation only if margins can expand.

No dividend has been paid on DMVF3.

What it is doing now

The company filed its full-year financial statements in March 2025 and held its annual shareholder meeting in late April 2026. In May 2024, Profarma formally increased its direct investment in d1000’s shares, tightening parent control over the subsidiary’s capital structure.

In early 2026, Brazil’s securities regulator (CVM) opened an inquiry into d1000’s investor-relations director over disclosure failures, including the non-provision of required documents ahead of a December 2024 shareholder meeting, failure to publish a board election minute within the required window, and a delayed update to the company’s reference form. The IR director agreed to pay BRL 277,200 (US$54 k)to settle the case — a modest penalty, but a reminder that disclosure standards demand strict attention.

What to watch

• Margin expansion or erosion. Revenue is growing fast but profit margins are near the floor. Whether the company can convert scale into thicker margins is the central question for any investor.
• Governance standards. The 2026 CVM settlement over disclosure lapses signals that internal controls need strengthening as the company grows and its public shareholder base widens.
• Profarma’s strategic intent. With 77.9% of shares controlled by insiders and Profarma adding to its stake in 2024, a full take-private or restructuring of the listed vehicle is a plausible scenario.
• Store expansion pace. Growth at 23% a year implies rapid new openings; whether new stores reach profitability quickly enough to sustain the earnings line is worth tracking quarter by quarter.

This is news, not investment advice.